Numerous studies on PD-L1 expression as a predictive biomarker have revealed that improved response rates in kidney cancer, melanoma, and non-small-cell lung cancer (NSCLC) are associated with higher PD-L1 levels [73]. The gene discussed is CD274; the disease is melanoma.